0
0
A team of researchers at the University of Edinburgh has unveiled a groundbreaking biotechnology that could transform the way we tackle both plastic pollution and pharmaceutical production. By re-engineering the common gut bacterium Escherichia coli, the scientists have demonstrated a process that converts the building blocks of discarded plastic bottles into paracetamol—the active ingredient in one of the world’s most widely used painkillers—in less than a day.
From Plastic Bottles to Medicine
Most disposable water and soft-drink bottles are made from polyethylene terephthalate (PET), a plastic of which over 350 million tons are produced annually, with only a small fraction being recycled. Traditional recycling methods often “down-cycle” PET into lower-value materials that ultimately become waste. The Edinburgh team approached the problem differently: they broke PET down into terephthalic acid (TPA), then used standard chemical steps to modify TPA into a form that E. coli could absorb. The bacteria’s metabolism was then rewired so that, once inside, it converted the compound into paracetamol through a series of biochemical reactions.
One of the key innovations is the use of a reaction called the Lossen rearrangement, which typically requires harsh laboratory conditions. Remarkably, the modified bacteria perform this reaction at room temperature in water, generating negligible carbon dioxide emissions.
Sustainable and Scalable Production
In laboratory tests, the engineered E. coli converted up to 90% of the PET-derived compound into paracetamol within 24 hours. While the current yield means each one-liter bottle could produce about nine standard 500 mg tablets, the researchers believe the process can be dramatically scaled up. The entire conversion happens in a single “one-pot” fermentation, similar to beer brewing, and requires no extreme heat or pressure, resulting in a much lower carbon footprint compared to conventional petrochemical production.
Broader Implications and Future Prospects
The study’s senior author, Professor Stephen Wallace, emphasized the broader potential: “This work demonstrates that PET plastic isn’t just waste or a material destined to become more plastic. It can be transformed by microorganisms into valuable new products, including those with potential for treating disease”.
The technology is part of a growing field called engineering biology, which combines genetic engineering, metabolic design, and traditional chemistry to create living “microbial factories.” Similar methods are already used at scale to produce drugs like insulin and the antimalarial artemisinin precursor.
Challenges Ahead
Despite the promise, several hurdles remain before this process can compete with conventional pharmaceutical manufacturing. Scaling up to industrial bioreactors, ensuring consistent bacterial performance, and meeting stringent regulatory standards for medicine purity are all challenges that must be addressed. Additionally, the process for breaking down mixed PET waste into pure TPA needs to be optimized for cost and efficiency.
A Glimpse of a Circular, Low-Carbon Future
This breakthrough provides a striking vision of a future where waste and resource boundaries blur, and where healing the planet could go hand in hand with healing people. While it does not solve the plastic crisis or secure global drug supplies on its own, it opens new avenues for sustainable chemical and pharmaceutical production.
Disclaimer:
This article is based on recent research findings published in Nature Chemistry and reports from the University of Edinburgh. The described technology is at the proof-of-concept stage and not yet available for commercial or medical use. Further research, regulatory approvals, and industrial scaling are required before such processes can be widely adopted.
